Assessing the social value of novel regimens for MDR TB

Location

Baltimore, Maryland, US

Dates

07/01/2014 - 06/01/2015

PI

David Dowdy, MD, PhD

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation that also incorporate considerations of social value, using novel regimens for MDR-TB as a paradigmatic example.

Projects

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

Enhancing models of HIV,viral hepatitis,...

The goal of this five-year project is to assist the United States Centers for Disease Control and Prevention in their approach...

Read More

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More